請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45795
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李繼忠,葉力森 | |
dc.contributor.author | Chien-Hsin Kuo | en |
dc.contributor.author | 郭建新 | zh_TW |
dc.date.accessioned | 2021-06-15T04:46:16Z | - |
dc.date.available | 2010-08-06 | |
dc.date.copyright | 2010-08-06 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-05 | |
dc.identifier.citation | 1. Withrow SJ, Vail DM. Withrow & MacEwen's small animal clinical oncology. St. Louis, Mo. :: Saunders Elsevier, 2007.
2. Ferguson HR. Canine mammary gland tumors. Vet Clin North Am Small Anim Pract 1985;15:501-511. 3. Novosad CA. Principles of treatment for mammary gland tumors. Clin Tech Small Anim Pract 2003;18:107-109. 4. Paridaens R. Efficacy of paclitaxel or doxorubicin used as single agents in advanced breast cancer: a literature survey. Semin Oncol 1998;25:3-6. 5. Simon D, Knebel JW, Baumgartner W, et al. In vitro efficacy of chemotherapeutics as determined by 50% inhibitory concentrations in cell cultures of mammary gland tumors obtained from dogs. Am J Vet Res 2001;62:1825-1830. 6. Simon D, Schoenrock D, Baumgartner W, et al. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 2006;20:1184-1190. 7. Howe LR, Dannenberg AJ. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 2002;29:111-119. 8. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-160. 9. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99:13926-13931. 10. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 1992;89:7384-7388. 11. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-1188. 12. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999;29:688-696. 13. Hwang D, Scollard D, Byrne J, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-460. 14. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-990. 15. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-3764. 16. Dickens DS, Kozielski R, Khan J, et al. Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol 2002;5:356-364. 17. Chen WS, Wei SJ, Liu JM, et al. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 2001;91:894-899. 18. Dore M, Lanthier I, Sirois J. Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol 2003;40:207-212. 19. Heller DA, Clifford CA, Goldschmidt MH, et al. Cyclooxygenase-2 expression is associated with histologic tumor type in canine mammary carcinoma. Vet Pathol 2005;42:776-780. 20. Brunelle M, Sartin EA, Wolfe LG, et al. Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines. Vet Pathol 2006;43:656-666. 21. Knottenbelt C, Chambers G, Gault E, et al. The in vitro effects of piroxicam and meloxicam on canine cell lines. J Small Anim Pract 2006;47:14-20. 22. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000;18:724-733. 23. Shen Q, Brown PH. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia 2003;8:45-73. 24. Waters EA, Cronin KA, Graubard BI, et al. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev;19:443-446. 25. Howe LR, Subbaramaiah K, Brown AM, et al. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001;8:97-114. 26. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-366. 27. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-1311. 28. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-596. 29. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716. 30. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501. 31. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-3340. 32. Nakatsugi S, Ohta T, Kawamori T, et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 2000;91:886-892. 33. Kubatka P, Ahlers I, Ahlersova E, et al. Chemoprevention of mammary carcinogenesis in female rats by rofecoxib. Cancer Lett 2003;202:131-136. 34. Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278. 35. Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J Vet Intern Med 2003;17:136-144. 36. Pan YY, Xu SP, Jia XY, et al. Combination of cyclooxygenase-2 inhibitor and doxorubicin increases the growth inhibition and apoptosis in human hepatocellular carcinoma cells. Exp Oncol 2007;29:23-29. 37. Yip-Schneider MT, Sweeney CJ, Jung SH, et al. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther 2001;298:976-985. 38. Sugiura T, Saikawa Y, Kubota T, et al. Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo. In Vivo 2003;17:229-233. 39. Wolfesberger B, Hoelzl C, Walter I, et al. In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells. J Vet Pharmacol Ther 2006;29:15-23. 40. Mohammed SI, Craig BA, Mutsaers AJ, et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2003;2:183-188. 41. Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005;3:73-80. 42. Momparler R. In vitro systems for evaluation of combination chemotherapy. Pharmacol Ther 1980;8:21-35. 43. Wolfesberger B, Walter I, Hoelzl C, et al. Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Res Vet Sci 2006;80:308-316. 44. Tsubouchi Y, Mukai S, Kawahito Y, et al. Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res 2000;20:2867-2872. 45. Busch U, Schmid J, Heinzel G, et al. Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos 1998;26:576-584. 46. Royals SR, Farese JP, Milner RJ, et al. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res 2005;66:1961-1967. 47. Knapp DW, Chan TC, Kuczek T, et al. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995;56:801-805. 48. Lees P, Landoni MF, Giraudel J, et al. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest. J Vet Pharmacol Ther 2004;27:479-490. 49. Chang SH, Liu CH, Wu MT, et al. Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor. Prostaglandins Other Lipid Mediat 2005;76:48-58. 50. Hoang BH, Dyke JP, Koutcher JA, et al. VEGF expression in osteosarcoma correlates with vascular permeability by dynamic MRI. Clin Orthop Relat Res 2004:32-38. 51. P'Eng F K, Wu CW, Chang TJ, et al. A comparison of regional versus systemic drug injection. Adriamycin concentration in peripheral blood and gastric stump (post-Billroth II gastrectomy) in the dog. Cancer Chemother Pharmacol 1989;23:363-366. 52. Ferrandina G, Lauriola L, Distefano MG, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002;20:973-981. 53. Ferrandina G, Lauriola L, Zannoni GF, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002;13:1205-1211. 54. Duffy CP, Elliott CJ, O'Connor RA, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998;34:1250-1259. 55. Lau L, Hansford LM, Cheng LS, et al. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene 2007;26:1920-1931. 56. Munkarah AR, Genhai Z, Morris R, et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells. Gynecol Oncol 2003;88:429-433. 57. Hattori K, Matsushita R, Kimura K, et al. Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth. Biol Pharm Bull 2001;24:1214-1217. 58. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004;31:2-11. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/45795 | - |
dc.description.abstract | 化學治療應用於治療已轉移之犬乳腺腫瘤的療效仍未完全確定。然而,近期有許多研究指出應用COX-2拮抗劑於犬乳腺腫瘤細胞時具有抗腫瘤的效果。本研究的目的在於體外培養的犬乳腺腫瘤細胞環境中,評估合併使用COX-2拮抗劑和Doxorubicin的藥理作用及抗腫瘤效果。將Meloxicam的濃度分別調配為1、2、4、10、50、100和200 μM,Doxorubicin的濃度分別調配為62.5、125、250、500、1000和2000 nM,添加兩種不同濃度藥物至已貼附犬乳腺瘤細胞的96孔盤內繼續培養72小時後,研究各個不同濃度的藥物下對犬乳腺腫瘤細胞抑制生長的效果。將各個不同濃度的Meloxicam及Doxorubicin交互混合成42種不同濃度的組合,同樣的也培養72小時後評估對犬乳腺腫瘤細胞的抑制效果。細胞存活分析是透過MTT來做檢測。Meloxicam及Doxorubicin組別的IC50 分別為93.57 μM及343.94 nM。然而,發現Meloxicam及Doxorubicin的IC50濃度之間的藥理相互作用為相加的藥理作用。低劑量的Meloxicam不僅單獨使用時沒有抑制乳腺腫瘤細胞生長的效果,而在比較併用低劑量的Meloxicam和各個Doxorubicin濃度與單用Doxorubicin的效果時,發現並沒有顯著差異的作用。只有高劑量的Meloxicam濃度單獨使用下有抑制乳腺腫瘤細胞生長的效果,而高劑量的Meloxicam濃度併用各個Doxorubicin濃度下皆有具有顯著差異的相加效果。 | zh_TW |
dc.description.abstract | Efficacy of chemotherapy in treatment of canine metastatic mammary gland tumor (MGT) has not been well established yet. However, many studies had documented COX-2 inhibitor used alone has shown antitumor activity in canine MGT recently. The purpose of present report is to evaluate the pharmacological and tumoricidal effect of the combination of COX-2 inhibitor with doxorubicin on established canine MGT cell lines and hypothesize the combination would have synergistic effect. To study the effect of different concentration of meloxicam (1, 2, 4, 10, 50, 100 and 200 μM), and doxorubicin (62.5, 125, 250, 500, 1000 and 2000 nM) on the proliferation of MGT cells, both groups are cultured for 72 hours. All concentrations of meloxicam and doxorubicin are combined to result in 42 different concentration combinations and incubated for 72 hours. Cell proliferation is assessed using a standard MTT assay. The IC50 of meloxicam and doxorubicin is 93.57μM and 343.94 nM, respectively. Exposure of tumor cells to IC50 combinations of meloxicam and doxorubicin reveal only sub-additive effect. The result of cell proliferation in the lower concentration of meloxicam group does not show inhibitive effect in CMT-1 cell line. The combination effect of lower concentration of meloxicam and any concentration of doxorubicin compared with the doxorubicin group do not reveal statistically significant effect in CMT-1 cell line. However, the result of cell proliferation in the higher concentration of meloxicam group shows statistically significant inhibitive effect in CMT-1 cell line, and the combination effect of higher concentration of meloxicam and any concentration of doxorubicin revealed statistically significant sub-additive effect with using doxorubicin alone. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T04:46:16Z (GMT). No. of bitstreams: 1 ntu-99-R96643009-1.pdf: 373960 bytes, checksum: 85aff1d90c9d1a7ff913b2f5488d03f5 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 口試委員審定書…………………………………………………… I
Acknowledgement……………………………………………….. II Abstract (Chinese)…………………………………………….. III Abstract……………………………… ………………………... IV Chapter I: Introduction…………………………………….... 1 Chapter II: Literature Reviews…..……………………….. 5 Chapter III: Aims…………………………………………………………………. 15 Chapter IV: Materials and Methods.………………………… 17 4.1 Cell Lines………………………………………………… 18 4.2 Culture Medium…………………………………………… 18 4.3 Cell Proliferation Assay……………………………… 18 4.4 Statistical Analysis…………………………………. 19 Chapter V: Results……………………………………………………………. 21 5.1 Growth Rate Assay with Meloxicam..………………… 22 5.2 Growth Rate Assay with Doxorubicin………………… 22 5.3 Growth Rate Assay with Meloxicam and Doxorubicin…22 Chapter VI: Discussion………………………………………… 25 Referrences………….………………………………………………39 Appendix...………….………………………..……………... 48 | |
dc.language.iso | en | |
dc.title | 評估併用Meloxicam和Doxorubicin於體外培養犬乳腺瘤細胞株(CMT-1)的效果 | zh_TW |
dc.title | In Vitro Effects of Meloxicam with Doxorubicin on Canine Mammary Gland Tumor Cell Line (CMT-1) | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林中天,闕玲玲 | |
dc.subject.keyword | Meloxicam,Doxorubicin,犬乳腺瘤, | zh_TW |
dc.subject.keyword | Meloxicam,Doxorubicin,Canine mammary gland tumor, | en |
dc.relation.page | 48 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-05 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床動物醫學研究所 | zh_TW |
顯示於系所單位: | 臨床動物醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 365.2 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。